The Lancet has published a correction for a landmark meta-analysis on ovarian ablation therapies for early-stage breast cancer. The notice, appearing in the journal's Department of Error section, specifies that figure 2 and figure 3 in the original article were updated.
The original analysis, published earlier in 2026, examined data from 15,000 women across 23 randomized trials. The study, conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), assessed the effects of ovarian ablation or suppression on recurrence and survival rates.
Corrections to published figures in high-impact journals like The Lancet are not uncommon but require careful scrutiny. The journal states the updates have been applied to the online version as of May 19, 2026, yet the specific nature of the errors or their potential impact on the study's conclusions has not been disclosed.
Readers and clinicians relying on the meta-analysis should review the corrected figures to ensure their understanding of the data remains accurate. The EBCTCG has not issued a separate statement regarding the corrections.
The correction did not alter the study's abstract or overall conclusions, according to the notice. No other figures or text in the article were affected.